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Abstract 
Degree project in medicine: Uric acid levels in arthralgia patients - Mathilda Mybeck 
Sahlgrenska University Hospital and Department of Rheumatology and Inflammation 
Research, University of Gothenburg, Sweden 2018 
 
Background: Uric acid is often associated with gout, but recent studies have attracted 
attention to a potential connection between rheumatoid arthritis (RA) and uric acid. It has 
been shown that RA patients with hyperuricemia have a milder joint disease, and that it is 
more common for patients who do not have RA-specific autoantibodies to have urate crystal 
deposits in their joints.  
 
Objectives: To examine the connection between uric acid and RA and to find out if there is a 
connection between uric acid and RA-specific autoantibodies or survivin.   
 
Material and methods: 338 patients were collected from the material of 1743 patients with 
arthralgia visiting the rheumatology clinic at Sahlgrenska university hospital during one year. 
All patients included had at least one measured serum uric acid level. Hyperuricemia was 
defined by the levels >400 mol/l for females and >480 mol/l for males. The patients were 
divided into groups depending on gender, rheumatic diagnose, antibodies, survivin and uric 
acid level. Symptoms of gout were investigated in 152 patients. 
 
Results: 34 % of all studied patients included had hyperuricemia. 95 % of the patients 
diagnosed with gout had hyperuricemia. Prevalence of hyperuricemia was higher in males 
than females (P<0.0002). Among the females with hyperuricemia, RA was the most common 
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diagnosis (40%). However, symptoms indicating gout, were significantly less in RA patients 
compared to gout (females P=0.0006, males P<0.0001). Regardless of antibodies and 
presence of survivin, the prevalence of hyperuricemia was similar (9/25 vs 44/114, P=0.82 for 
males and 11/33 vs 51/166, P=0.76 for females). There was no difference in uric acid level 
depending on rheumatic diagnose, except for gout which had significantly higher levels of 
uric acid (P<0.0001).     
 
Conclusions: Hyperuricemia was attributed to the diagnosis of gout and showed its 
specificity regardless of autoantibody and serum survivin profile.  
 
Key words: Rheumatoid arthritis, uric acid  
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Abbreviations 
RA: Rheumatoid arthritis 
ALG: Arthralgia 
UA: Undifferentiated arthritis 
HU: Hyperuricemia 
CHU: Clinically significant hyperuricemia 
RF: Rheumatoid factors 
ACPA: Anti-citrullinated protein antibody 
aCCP: Anti-cyclic citrullinated peptide antibody  
AMP: Adenosine monophosphate 
GMP: Guanosine monophosphate 
DNA: Deoxyribonucleic acid 
RNA: Ribonucleic acid 
DECT: Dual Energy Computed Tomography 
HGPRT: Hypoxanthine-guanine phosphoribosyltransferase 
MTP: Metatarsophalangeal joint 
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Introduction 
Uric acid 
Metabolism 
Uric acid (C5H4N4O3) is the end product of the purine metabolism in humans. Starting from 
AMP and GMP, purines are derived multiple times. An important step is conversion to 
guanine and adenine, which are two of the nucleotides in DNA and RNA [1]. Formation of 
DNA is one function of purines, along with signal transduction and modulation of energy 
metabolism. Purines are from guanine and adenine via several conversions degraded to 
xanthine, and then to uric acid. Humans do not have the enzyme uricase which breaks uric 
acid down further into allantoin in most other mammals, and therefore uric acid is the end 
product in humans (figure 1). Uric acid is instead excreted via the kidneys (2/3) and the 
gastro-intestinal tract (1/3) [2]. Uric acid has also been shown to be an important antioxidant, 
responsible for neutralisation of 2/3 of all free radicals [3]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Metabolism of purines. Enzymes are shown in red. Purines are 
degraded from AMP and GMP to uric acid. IMP, inosine monophosphate; 
HGPRT, hypoxanthine-guanine phosphoribosyltransferase.  
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Causes of hyperuricemia 
When the level of uric acid in the blood circulation is high, hyperuricemia occurs. This might 
lead to crystallisation of uric acid, and further to deposition of monosodium crystals in organs 
and tissues and also in joints, which got the name of gout. Gout is characterised by severe 
pain and joint redness, often in first metatarsophalangeal joint (MTP 1). Risk factors for gout 
include high consumption of alcohol and purine rich food such as red meat, as well as obesity 
[4]. The crystallisation of uric acid that occurs in gout is more common at a level of uric acid 
in the blood above 360 mol/L [5]. There are several reasons for hyperuricemia, these can be 
categorised as an increased production of uric acid, a decreased elimination of uric acid or a 
combination of the two. Increased production of uric acid can, for instance, be a consequence 
of the increased cell destruction that occurs in lysis of tumour cells in leukemia [6], and it has 
been shown to occur after chemotherapy [7]. Decreased elimination of uric acid can be caused 
by acidosis, which causes decreased tubular filtration of uric acid in the kidneys due to an 
increase in organic acids which inhibits filtration of uric acid [8]. This can be seen in diabetes 
ketoacidosis, high alcohol consumption or famine. Decreased elimination of uric acid can 
further be due to kidney disease. Hyperuricemia can also be a consequence of genetic 
disorders that affects enzymes related to metabolism of uric acid. Two examples are the 
genetic diseases Lesch-Nyhan syndrome and Kelley-Seegmillers syndrome, which both are 
related to deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase 
(HGPRT). This enzyme is involved in the metabolism of uric acid as seen in figure 1, and 
inadequate function can cause hyperuricemia [9].  
 
Reference range of uric acid 
Currently, the reference range for uric acid used in Sweden and internationally is 155-400 
mol/L for females and 230-480 mol/L for males. This is calculated from the healthy 
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population and is adjusted according to the changing uric acid levels in the population, where 
increasing prevalence of obesity leads to a higher mean uric acid level in the population and 
therefore a higher reference range for uric acid [5]. It has been debated whether the reference 
range for uric acid should be decreased. It has been proposed that the cut-off values for uric 
acid should, instead of being determined by the uric acid levels in healthy population, be 
determined by the physiological traits of uric acid. Zhang et. Al. proposed a cut-off value of 
291 mol/L in females and 375 mol/L in males [10]. New evidence have shown that there is 
a risk for cardiovascular disease, even at a uric acid level within today’s reference range [11] 
and this justifies a potential lowering of the uric acid reference range to open up for earlier 
treatment.   
 
Rheumatoid arthritis  
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by synovial 
inflammation and destruction of joints. The prevalence of RA is today estimated to 0.1 to 1 
percent of adults in developed countries [12]. With the discovery of disease modifying 
antirheumatic drugs (DMARD) and biologic agents the possibilities of treatment and the 
prognosis have improved substantially during the 21st century. 
  
Autoantibodies in rheumatoid arthritis 
The main antibodies used for diagnosis and disease monitoring of RA are RF and ACPA. RF 
is an abbreviation for rheumatoid factor and was first found in 1940. It has a specific antigen, 
the Fc-region of the IgG antibody molecule, and occurs in about 50 % of RA patients, but also 
among healthy individuals. It is a useful marker of RA, and associates with poor prognosis 
and severe disease. ACPA stands for antibodies against citrullinated peptides and is found in 
about 50 % of RA patients. It is uncommon in other diseases and in the healthy population, 
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and the specificity and sensitivity is high. Similarly to RF, it is also associated with a poor 
prognosis [13]. Clinically, the most common analysis to measure ACPA is analysis of aCCP 
(antibodies against cyclic citrullinated peptide). Both RF and ACPA have been shown to 
occur in patients for several years before symptoms of disease, and can therefore be 
considered important risk factors which often precedes the development of RA [14, 15].   
 
Survivin 
Survivin is an onco protein that controls cell divisions and functions as an inhibitor of 
apoptosis. It has recently been shown that elevated levels of survivin in serum predict 
development of RA. Survivin could function as an important diagnostic tool and a way to 
monitor patients with RA [16].      
 
Uric acid and its connection to rheumatoid arthritis 
Recent studies have drawn attention to the connection between RA and uric acid. It has been 
shown that hyperuricemia in patients diagnosed with RA correlates with a milder disease [17]. 
It has also been shown to be more common for patients negative for RF to have monosodium 
urate crystal deposits [18], indicating that uric acid indeed might have a connection with RA 
and that uric acid levels might vary depending on antibodies. Furthermore, patients diagnosed 
with RA have a higher risk of cardiovascular disease and mortality [19], and so does patients 
with hyperuricemia [20]. A possible explanation for the risk of cardiovascular disease in RA 
patients could be that RA patients in general have higher level of serum uric acid that elevates 
the cardiovascular risk [21]. It was reported that RA-patients with hyperuricemia had a higher 
risk of peripheral arterial events and a higher mortality rate, than patients who did not have 
hyperuricemia [22]. 
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It has also been debated to what extent RA and gout coexists in the same patient. This was 
earlier believed to be rare, with merely 33 reported patients in scientific literature in English, 
but the study addressing this question found that it occurred more often than believed, though 
not as often as in the general population. Also, incidence of gout has increased in the general 
population, and therefore so has incidence of gout in RA-patients [23].  
 
Taken together, the prevalence of both gout and hyperuricemia has been rising during the 21st 
century, and several studies have shown different possible connections between uric acid and 
RA. New knowledge is therefore important. The objective of this study was to examine the 
connection between uric acid and rheumatic joint diseases, and further investigate whether 
there is a connection between uric acid and antibodies or survivin. An additional purpose was 
to find out how prevalent symptoms indicating gout are among RA-patients. This was done 
using diagnostic rules for diagnosis of gout developed for primary care in 2010 for when joint 
fluid is not available [24].  
 
Aim 
To examine the connection between uric acid and RA, and to find out if there is a connection 
between uric acid and autoantibodies or survivin. In addition, to investigate symptoms of gout 
in RA-patients.  
Ethics 
The study was approved by the Ethics Committee of Gothenburg, in accordance to UN’s 
declaration on human rights and the Declaration of Helsinki. Ethics committee approval 
number: 257-13.  
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Patients and Methods  
Selection of the patient cohort 
In total, 338 patients were selected from a larger material of 1743 patients with arthralgia 
visiting the Rheumatology Clinic at the Sahlgrenska University Hospital, Gothenburg during 
12 consecutive months between November 2012 to November 2013 (figure 2). Inclusion 
criteria were, aside from having one measurement of RF and aCCP, at least one measurement 
of uric acid at the Laboratory of Clinical Chemistry, SU, and clinical assessment by 
rheumatologist in adjustment to the blood sampling.  
 
All patients were labelled with gender, age, diagnosis and positive or negative RF, aCCP and 
survivin-protein. Serum uric acid levels were noted. The patients were further divided into six 
groups depending on diagnose and formed the groups with 1) rheumatoid arthritis (RA), 2) 
gout, 3) undifferentiated arthritis (UA; which included monoarthritis, oligoarthritis, 
polyarthritis and reactive arthritis), 4) spondyloarthritis and psoriasisarthritis (SpA/PsA) 5) 
Figure 2. Chart flow diagram of the patients included. Of 1743 patients visiting the 
Rheumatology Clinic at Sahlgrenska University Hospital, 338 were included in the 
study and analysed in respect of uric acid. 152 patients of the 338 patients were 
investigated for symptoms of gout. 
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arthralgia (ALG) (table 1). In addition, one group contained the patients with other diagnoses 
and it included osteoarthritis, polymyalgia rheumatica, systemic lupus erythematosus, 
tendinitis or uncertain diagnose. This subdivision into groups was based on diagnoses set at 
the first visit and classified according the International Classification of Diseases. 
 
Collection of clinical material from medical records 
Medical records from 152 patients diagnosed with gout, RA or categorized as “other 
diagnose” were carefully reviewed for the signs and symptoms of gout, using the diagnostic 
rules for diagnosis of gout (table 3). It includes the following parameters: Uric acid level 
above 350 mol/L (3.5 points), male gender (2 points), previous gout attack (2 points), debut 
of symptoms within 24 hours (0.5 points), joint redness (1 point), involvement of the first 
MTP joint (2.5 points) and hypertension or one or more cardiovascular diseases (1.5 points). 
The points were added and a “gout-score” was calculated. The information was collected 
from medical records, Sahlgrenska University Hospital.  
 
Measurement of the uric acid in serum 
Uric acid was measured at the Laboratory of Clinical Biochemistry at the Sahlgrenska 
University Hospital. Clinically significant hyperuricemia (CHU) was defined as serum uric 
acid level >400 mol/L for females and 480 mol/L for males, this is the range used by the 
laboratory of Clinical Chemistry, SU. In addition, serum uric acid values above 300 for 
females and 400 for males were labelled as hyperuricemia (HU), due to recent findings 
suggesting that even an increase in uric acid level that is within the reference range can have 
consequences in health. 
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Measurement of RA specific antibodies: aCCP and RF 
RA specific antibodies were measured at the accredited laboratories of the Clinical 
Immunology at the Sahlgrenska University Hospital. aCCP was measured using an automatic 
multiplex method (anti-CCP2, BioRad, Hercules, CA), with cut-off value 3.0 U/ml. RF was 
measured by rate nephelometric technology (Beckman Immage 800, Beckman Coulter AB, 
Brea, CA), with a cut-off value of 20 U/ml.     
 
Measurement of serum survivin 
Serum survivin was measured using ELISA (DY647, R&D Systems, Minneapolis, MN). The 
cut-off value was calculated from 104 healthy individuals and set to 450 pg/ml [25].  
 
Statistical analysis 
For statistical analyses, various methods were used, depending on what was investigated. 
Graphpad prism version 7 were used for ANOVA and Chi square tests. ANOVA stands for 
“Analyses of variance” and was used to compare means and medians among groups. Chi 
square tests were used for comparison of prevalence among two or more groups. 
Www.openepi.com was used for two by two tables when comparing prevalence in two 
groups. Descriptive results are presented as median [1st quartile – 3rd quartile]. 
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Results 
Clinical and demographic characteristics of the patient cohort 
In total, 338 patients were included in the study, 198 females and 140 males. The median age 
was 60 years (range 48-68). Characteristics of all patients included are presented in Table 1. 
  
Table 1. Patients characteristics. Results are showed as median and 1st and 3rd quartile. 
Categorical variables showed as n (%). Other diagnoses include for example arthrosis, 
polymyalgia rheumatic, systemic lupus erythematosus, tendinitis or uncertain diagnose. SpA, 
spondyloarthritis; PsA, psoriasisarthritis; IQR, interquartile range.  
 All participants  
n=338 
Females 
n=198 
Males 
n=140 
Age, years, median [IQR] 60 [48-68] 56 [45-67] 61 [52-69] 
Uric acid, umol/L 
 median [IQR] 
300 [244-376] 267 [223-316] 373 [301-458] 
Hyperuricemia, n (%)  114 (34%) 61 (31%) 53 (38%) 
Clinically significant hyperuricemia, n 
(%) 
44 (13%) 15 (8%) 29 (21%) 
Rheumatoid arthritis (%) 84 (25%) 55 (28%) 29 (21%) 
Gout (%) 42 (12%) 11 (6%) 31 (22%) 
Undifferentiated arthritis (%) 46 (14%) 24 (12%) 22 (16%) 
Arthralgia (%) 55 (16%) 46 (23%) 9 (6%) 
SpA/PsA (%) 26 (8%) 14 (7%) 12 (9%) 
Other diagnoses (%)  87 (26%) 48 (24%) 37 (26%) 
 
 
The median levels of uric acid in serum were 300 mol/L (range 244 to 376). As expected, 
among the male patients the median level of uric acid was significantly higher than among the 
female patients (median 373 mol/L vs. 267 mol/L, p<0.0001. Table 1). Due to the 
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difference in uric acid level between males and females, the groups were mostly analysed 
separately. 
 
The diagnoses differed in male/female ratio (figure 3). Females were more common in the 
ALG group, and males were more common in the gout-group. Remaining groups were more 
similar, but RA had a tendency towards the female gender.  
 
 
 
 
 
 
 
When comparing uric acid levels among the groups with different diagnoses, patients with 
gout (31 males and 11 females) had significantly higher level of uric acid than all other 
groups (P<0.0001 for both males and females, figure 4). Few patients diagnosed with gout 
were positive for RF and/or aCCP (10% of the males and 18 % of the females). There was no 
significant difference in age between the groups. 
Figure 3. Gender distribution within the diagnoses. Number of females 198, number of males 
140. ALG, arthralgia; RA, rheumatoid arthritis; SpA, spondyloarthritis; PsA, 
psoriasisarthritis; UA, undifferentiated arthritis.  
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Prevalence of CHU is higher among males than females 
Males have higher absolute levels of uric acid in general and that was also the case in this 
material (table 1). Therefore, males and females have separate reference intervals for uric acid 
levels, with different threshold limits for HU (see method). In total, 53 of 140 males (38 %) 
and 61 of 198 females (31 %) had HU. Males had significantly higher prevalence of CHU 
than females, 21% (29 of 140) compared to 8 % (15 of 198) (p=0.0005, OR 3.18, [95% CI 
1.64-6.33]. Figure 5). There was no significant difference in prevalence of HU (53/140 vs 
61/198, P=0.18, OR 1.37, [95% CI 0.87-2.16]). 
  
 
 
 
 
 
Figure 4. The levels of uric acid in patients with different diagnoses. Male patients 
(n=140) had higher levels of uric acid compared to females (n=198). The patients with 
gout had significantly higher levels of uric acid compared to all other groups (ANOVA, 
p<0.0001).    
Figure 5. Hyperuricemia (HU) and clinically significant hyperuricemia (CHU) 
among the male and female patients. Number of males 140, number of females 198. 
Tested with Chi Square. Significant difference in prevalence of CHU between males 
and females, P=0.0005.   
0% 25% 50% 75% 100%
Males
Females
Males and females, HU and CHU
CHU
HU
No HU
P=0.0005
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The difference in CHU was due to high number of patients with gout among the males. The 
prevalence of HU or CHU was similar between males and females with non-gout diagnosis 
(HU: 28/110 vs. 51/187, P=0.74. CHU: 12/110 vs. 11/187, P=0.13). 
 
Prevalence of HU and uric acid levels is similar in RA and other rheumatic diseases, 
with the exception for gout 
When comparing the prevalence of HU in RA to other rheumatic diseases, there was no 
significant difference, except for gout. Patients diagnosed with gout had higher prevalence of 
HU than patients diagnosed with RA (P<0.0001, for both males and females, figure 6). Male 
patients with gout also had higher prevalence of CHU than male patients with RA. There was 
no such significant difference in CHU seen among females with gout compared to females 
with RA (6/56 vs 4/12, P=0.079). 
 
  
 
Figure 6. Prevalence of hyperuricemia (HU) in patients with different diagnoses. HU was 
significantly more prevalent in gout compared to RA. Other diagnoses were similar in prevalence 
of HU compared to RA. Males (n=140), females (n=198). RA, rheumatoid arthritis; Spa, 
spondyloarthritis; PsA, psoriasisarthritis; ALG, arthralgia; UA, undifferentiated arthritis; OR, 
odds ratio; CI, confidence interval.  
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Uric acid was not connected to RF, aCCP and survivin 
In total, 25 males and 33 females were positive for the RA-specific antibodies RF and/or 
aCCP (AB+), and 98 females and 55 males were positive for survivin (Surv+). The patients 
were divided into groups based on antibody and survivin positivity and the levels of uric acid 
were compared. The groups were very similar, there was no connection seen between aCCP, 
RF, survivin and prevalence of hyperuricemia in non-gout patients or gout-patients (figure 7). 
There was further no connection between antibodies, survivin and uric acid levels (ANOVA 
for males P=0.80, for females P=0.97). 
Figure 7. Prevalence of hyperuricemia (HU) depending on antibodies and survivin. Males and 
females are analysed separately. Patients with gout are not included in picture A and B. No 
significant difference in prevalence of HU was seen, Chi square test for males P=0.739, for females 
P=0.965. C and D shows gout-patients. Surv, survivin; AB, antibodies; HU, hyperuricemia.   
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Among the 84 patients diagnosed with RA were 65% females, and 37 patients (44 %) were 
positive for RF and/or aCCP. 51 patients (61 %) were positive for survivin. There was no 
significant difference in uric acid levels (ANOVA for males P=0.56, for females P=0.57) or 
prevalence of HU (Chi Square test, P>0.05 for both males and females) in the groups with 
high and low levels of antibodies or of survivin.   
 
All seropositive patients were divided into groups depending on antibodies (positive RF or 
positive aCCP, both positive RF and aCCP and negative) (table 2). There was no significant 
difference in uric acid levels depending on antibodies (ANOVA for males P=0.49, for females 
P=0.62). Moreover, there was no significant difference in prevalence of HU (Chi Square test 
for males P=0.72, for females P=0.53) or CHU (Chi Square test for males P=0.81, for females 
P=0.80). 
  
Table 2. Comparing patients positive for aCCP or RF (n=40), patients positive for aCCP and 
RF (n=18) and patients negative for aCCP and RF (n=280). HU, hyperuricemia; CHU, 
clinically significant hyperuricemia; AB, antibodies; RF, rheumatoid factor; aCCP, anti-cyclic 
citrullinated peptide antibody; IQR, interquartile range.  
 Males  Females  
 Uric acid, 
median [IQR] 
HU, 
n/total 
CHU, 
n/total 
Uric acid, 
median [IQR] 
HU, 
n/total 
CHU, 
n/total 
aCCP+ or 
RF+  
n=40 
386 [308-440] 7/17 
(41%) 
4/17 (24%) 285 [240-334] 9/23 
(39%) 
1/23 (4%) 
aCCP+ and 
RF+ 
n=18 
336 [296-380] 2/8 (25%) 1/8 (13%) 238 [223-283] 2/10 
(20%) 
1/10 (10%) 
AB- 
n=280 
373 [300-459] 44/114 
(36%) 
24/114 
(21%) 
267 [224-316] 51/166 
(31%) 
13/166 
(8%) 
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Uric acid level and age correlates in females 
In females there was a significant correlation between uric acid level and age (figure 8). At a 
higher age the uric acid levels tended to be higher as well (P<0.0001 and R=0.355). There 
was no significant correlation between uric acid and age seen among males.  
 
 
 
 
 
Figure 8. Male and female patients, serum uric acid level and age, correlation tested with Pearson. 
In A and B, gout-patients are excluded, in C and D, only gout-patients are included. A significant 
correlation was seen in A (R=0.355, P<0.0001). N, number of patients.  
n=109 n=187 
n=11 n=31 
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RA was the most common diagnosis among the female patients with CHU  
Among all patients with CHU, gout was the most common diagnosis among males, but not 
among females (figure 9). Among females, instead, RA was the most common diagnose. 
40 % of all female patients with CHU were diagnosed with RA, this compared to 27 % of the 
female patients who were diagnosed with gout. Furthermore, 20% of females and 24 % of 
males with CHU had other diagnoses.  
Clinical symptoms in gout and rheumatoid arthritis  
Using the symptoms of gout collected from medical records, patients diagnosed with gout 
were compared to patients diagnosed with RA (Table 3). The gout patients had significantly 
higher gout score than RA-patients, both males and females (P=0.0006 for females, P<0.0001 
for males, figure 10). It was not possible to retrieve information about all patients in the 
medical records. To investigate whether the information about the patients from the medical 
records were representative for the whole material, the patients included and the patients not 
included at the medical records were compared by age, gender, uric acid levels and presence 
of autoantibodies. There was no significant difference between the groups in any aspect.  
Hyperuricemia among females
Total=15
40.00%  RA
26.67%  Gout 
6.67%  ALG
6.67%  SpA/PsA
20.00%  Other diagnoses
Hyperuricemia among males
Total=29
3.45%  RA
58.62%  Gout 
6.90%  UA
6.90%  SpA/PsA
24.14%  Other diagnoses
Figure 9. Distribution of patients with clinically significant hyperuricemia by diagnoses. 
Females (n=198)  to the left and males (n=140) to the right. The most common diagnosis 
was gout among males (59 %) and RA among females (40 %). RA, rheumatoid arthritis; 
UA, undifferentiated arthritis; ALG, arthralgia; SpA, spondyloarthritis; PsA, 
psoriasisarthritis.  
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When comparing the individual criteria of the gout diagnostic rule there was significant 
difference between gout and RA in five of seven criteria (table 3, figure 11).    
 
Table 3. Comparing the individual criteria of the gout diagnostic rule among patients 
diagnosed with gout (n=29) and RA (n=73). RA, rheumatoid arthritis; MTP, 
metatarsophalangeal joint.  
 Gout RA 
Previous gout attack 20/29 (70 %) 1/73 (1 %) 
Serum uric acid level>350 mol/L 26/29 (90 %) 18/73 (25 %) 
Joint redness 3/29 (10%) 1/73 (1 %) 
Male sex 21/29 (72 %) 26/73 (36 %) 
Hypertension or ≥ cardiovascular 
diseases 
10/29 (34 %) 8/73 (11 %) 
Onset within 24 h 9/29 (31 %) 7/73 (10 %) 
MTP1 involvement 9/29 (31 %) 10/73 (14 %) 
Figure 10. Comparing gout score in gout and RA patients using Mann-Whitney test. Significantly 
higher points in gout-patients, females P=0.0006, males P<0.0001. RA, rheumatoid arthritis.  
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Among RA patients there was a significant correlation between uric acid level and gout score 
(P<0.0001, R=0.7479, figure 12). Among gout patients it was more common with higher gout 
score at a higher uric acid level as well, but this correlation was not significant (P=0.0534, 
R=0.362). 
 
 
  
Figure 12. Correlation between gout score and uric acid in RA and gout, tested 
with Pearson. RA shown in blue and gout in black. R value 0.748 for RA, 0.362 
for gout. RA, rheumatoid arthritis.  
Figure 11. Comparing gout diagnostic rule among patients diagnosed with gout 
(n=29) and RA (n=73). RA, rheumatoid arthritis; MTP, metatarsophalangeal 
joint. 
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In total, nine patients diagnosed with gout medicated with allopurinol at the time their uric 
acid level was measured. When comparing gout score among gout-patients who medicated 
with Allopurinol with gout-patients who did not medicate with allopurinol there was no 
significant difference between the groups (Mann Whitney, P=0.356). According to medical 
records, none of the patients diagnosed with RA were using allopurinol at the time of the 
blood test.  
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Discussion 
In this study the levels of uric acid were investigated in respect of gender, age, diagnosis, 
autoantibodies and survivin, particularly in connection to RA. Taken together, the analysis 
showed that RA patients had neither significantly different levels of uric acid than patients 
diagnosed with other rheumatic diseases, with the exception for gout, nor did the uric acid 
levels vary depending on aCCP, RF or survivin. Although RA was the most common 
diagnosis among female patients with hyperuricemia, the symptoms indicating gout were 
significantly more common among patients diagnosed with gout. 
 
In contrary to the results reported by Petsch et al. [18], we observed no significant difference 
in uric acid levels depending on autoantibodies. Patients positive for RF had a prevalence of 
HU comparable to the patients negative for RF. Neither were there any difference depending 
on aCCP or survivin. However, this study did not include assessment of urate deposits in 
tissues, which had been found more often in patients negative for RF than in RF-positive [18]. 
One hypothesis was that even marginally elevated uric acid levels, but within today’s 
reference range, could correlate with autoantibodies or survivin, but we did not see this either.     
 
One of our initial hypotheses was that hyperuricemia in RA could be a sign of the underlying 
cell cytotoxicity occurring in RA, similar to cell destruction in tumour lysis syndrome [26]. 
To investigate this, we compared the uric acid levels among six groups with different 
rheumatic diagnosis. The results from this study shows that HU does not seem to be an 
essential part of cell destruction in RA more than other rheumatic diseases. On the contrary, 
there was no significant difference in uric acid level or prevalence of hyperuricemia 
depending on disease, apart from gout. Some patients with RA have hyperuricemia, but not 
more than patients with, for instance, arthralgia. Thus, the levels of uric acid do not seem to 
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be a marker for cell destruction or a part of a destruction mechanism in RA. To be noted, this 
study did not measure on going cell damage. To understand how uric acid might be connected 
to cell damage it would have to be further investigated, for example by measuring a marker 
for on going cell destruction. One potential marker could be lactic dehydrogenase which is 
released from damaged cells and was proposed to predict joint damage in RA [27], but this 
marker is not reliable in clinical practice. Further studies are needed in this subject to 
investigate it. Another interesting aspect would be to include a group of healthy individuals to 
compare with.  
 
Among all patients with hyperuricemia, RA was the most common diagnosis among females. 
Although it is to be noted that the number of females with RA was higher than the number of 
female patients with gout included in this study, this was an interesting find. We hypothesized 
that it could potentially mean that patients diagnosed with RA are less prone to be examined 
for the signs of gout. Therefore, gout might be underdiagnosed in patients with RA. Also, 
symptoms of RA may mask symptoms of gout, and further postpone the diagnosis. It has been 
reported that coexisting RA and gout in the same patient is more common than what was 
previously believed, and that gout does occur in RA patients, but at a lower incidence than the 
general population [23].  
 
An underlying hyperuricemia/gout in a patient with RA is problematic, it could postpone the 
diagnosis of RA for years if the symptoms are interpreted as gout [28]. To address this issue, 
we performed a retrospective analysis of the medical records of the first visit of patients with 
RA and gout. The purpose of the medical records analysis was to investigate whether clinical 
symptoms of gout were similar in patients diagnosed with RA and with gout. The result of 
this analysis clearly showed that the patients diagnosed with RA had significantly less 
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symptoms of gout, than patients diagnosed with gout. When comparing the criteria of 
separately, all seven criteria of the gout diagnostic rule showed less symptoms of gout in RA, 
with significantly less symptoms in five criteria. In conclusion, RA patients did not have 
similar symptoms as gout. However, RA-patients with a higher uric acid level had more 
symptoms of gout, with a significantly higher gout score. Therefore, one can hypothesise that 
uric acid has an impact on the symptoms in RA-patients, even with no gout-diagnosis. We can 
also conclude that uric acid level is a good predictor of gout score in RA-patients.   
 
The correlation between age and uric acid found in this study could only be seen among 
females. This correlation allows suggestion that age, and not the clinical signs, is the major 
indicator for hyperuricemia in female RA-patients. The correlation between age and uric acid 
is also in line with previous studies, reporting that females have a difference in uric acid 
levels depending on age, with lower oestrogen level at a higher age resulting in higher uric 
acid level. It has been proposed that a decline in oestrogen levels could be connected to 
hyperuricemia [29]. This would explain why only females showed an age correlation between 
uric acid and age in our study (figure 8), and why this correlation was not seen among males.  
 
Methodological considerations 
Several limitations of this study should be appreciated. First, in this study hyperuricemia was 
the measured outcome, via measurement of uric acid levels in serum. Hyperuricemia does not 
necessarily mean that crystallization of uric acid has occurred, and therefore it is unclear if the 
symptoms are caused by uric acid, even if the uric acid level is elevated. A recently 
introduced way to diagnose gout is Dual Energy CT (DECT). DECT uses X-ray beams of two 
types of energy and can detect monosodium crystal deposits in tissue non-invasively with a 
low radiation dosage. It was reported to be a very good and effective screening method for 
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crystal deposits [18]. DECT was not used in this study, and to be sure of which patients have 
monosodium crystal deposits, and which symptoms are due to gout, DECT should be used. 
Secondly, according to the inclusion criteria, all patients were required at least one measured 
uric acid level, therefore the material might have been biased to patients who one way or 
another had a blood test analysed in respect of uric acid. Also, the diagnosis was determined 
in association to the blood test which means that later development of the disease was not 
taken into consideration. Moreover, the diagnoses were based on the ICD-code which was 
determined by each treating doctor, and the basis for selection of ICD-code is not fully 
standardised. Lastly, we did not have information about all factors which potentially could 
affect uric acid levels, for example body mass index and current medicines. It has been 
proposed that therapy with methotrexate might lower uric acid levels, due to an inhibition of 
enzymes in the purine metabolism, and an accumulation of adenosine as a consequence. It has 
been shown that patients treated with methotrexate had lower uric acid levels. It was also 
found that the patients with lower uric acid levels due to methotrexate treatment had better 
clinical status [30]. Information about the use of methotrexate was not collected for this study, 
and since this was a cross sectional study, collecting the data retrospectively would not 
produce any useful result. This might be a source of error and is also an interesting aspect of 
the connection between uric acid and RA which should be investigated further in future 
studies.  
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Conclusions 
Prevalence of HU and uric acid levels are similar in RA and other rheumatic diseases, with 
the exception for gout. Moreover, there was no significant connection between levels of uric 
acid and RF, aCCP and survivin. Prevalence of CHU is higher among males than females and 
in the female patients with CHU, RA was the most common diagnosis. The levels of uric acid 
also correlated positively to the age of female patients.  
 
In a wider perspective, this study contributes to the research field of rheumatoid arthritis and 
its connection to uric acid which was previously rather unexplored with only a few studies 
addressing the issue. Our study also supports the use of gout diagnostic rule for clinical 
diagnosis of gouty arthritis in primary care when joint fluid analysis is not available, which 
can be a helpful tool in the clinic.  
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Populärvetenskaplig sammanfattning på svenska: Uratvärden hos 
patienter med ledsjukdom 
Gikt och reumatoid artrit är två reumatiska sjukdomar som båda drabbar allt fler människor i 
Sverige. Gikt beror på att ämnet urat ansamlas i blodet vilket kan göra att kristaller av urat 
bildas. Om dessa kristaller ansamlas i leder kan detta leda till snabbt påkommande rodnad, 
svullnad och svår smärta. Det är framförallt vanligt att stortån drabbas. En gikt-attack går i 
regel över inom några veckor. Reumatoid artrit beror på att immunsystemet reagerar mot 
strukturer i kroppens egna celler och detta orsakar svullnad, ömhet, stelhet och smärta i leder. 
Vid reumatoid artrit är det vanligt att ha autoantikroppar, vilka är proteiner som ingår i 
kroppens immunförsvar och som riktar sig mot strukturer i kroppens egna celler vilket orsakar 
skada. I denna studie undersöktes kopplingen mellan urat-värde i blodet, ledsjukdomar såsom 
reumatoid artrit och gikt, samt autoantikroppar. Man har i tidigare studier sett att patienter 
med reumatoid artrit och högt urat kan ha en något lindrigare sjukdom. Man har även sett att 
det är vanligare med förhöjt uratvärde i blodet hos patienter med reumatoid artrit som är 
positiva för autoantikroppar än patienter som är negativa för autoantikroppar.  
 
Totalt 338 patienter inkluderades i studien. Samtliga patienter hade någon typ av ledbesvär 
och hade besökt reumatolog på Sahlgrenska universitetssjukhuset. Alla hade dessutom minst 
ett uppmätt uratvärde. Patienterna analyserades utifrån diagnos, kön, uratvärde och förekomst 
av autoantikroppar. Utöver detta studerades symtom vid besök till reumatolog hos 152 
patienter utifrån det diagnostiska hjälpmedlet för giktdiagnos för att ta reda på vilka patienter 
som hade symtom tydande på gikt.   
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Enligt våra resultat har inte urat-värden någon koppling till autoantikroppar vid reumatoid 
artrit. Man kan inte heller se att patienter med reumatoid artrit skulle ha högre urat-nivåer i 
blodet än patienter med andra ledsjukdomar. Däremot sågs, som förväntat, högre uratnivåer 
hos män än hos kvinnor samt hos patienter diagnosticerade med gikt. Bland kvinnliga 
patienter med förhöjda uratnivåer var den vanligaste diagnosen reumatoid artrit, men det 
diagnostiska hjälpmedlet för giktdiagnos visade inte på att det skulle vara vanligare med gikt-
symtom bland patienter med reumatoid artrit än patienter med gikt.  
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